Given the size of the stroke depicted in Figure 1 (greater than one third of the hemisphere), thrombolytic therapy would be contraindicated for this patient. Indications of a hemorrhagic stroke ...
Mistry described Scp776 as a “designer drug.” She explained that IGF-1 receptors are abundant throughout the body, and IGF-1 ...
Clinical Trials Arena on MSN
Bioxodes’ haemorrhagic stroke hopeful to progress after Phase II success
If approved, the drug could become the first treatment for haemorrhagic stroke outside of surgical intervention.
LT3001 (Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage occurred. Data suggest that LT3001 has the potential to provide significant clinical benefit to ...
Every moment is critical when treating a stroke. Ischemic strokes, which account for 87% of all strokes annually, occur when ...
Remedy Robotics selected as Mission Thrombectomy's exclusive robotics partner to broaden access to life-saving stroke treatment in the U.S. and across the world. SAN FRANCISCO and ...
For more than 40 years as a researcher and clinician, Joseph Broderick has actively contributed to improvements in stroke ...
Explore evolving treatments for brain aneurysms and strokes, highlighting advancements that promise better outcomes and ...
Corresponding author Akshay Sharma, MBBS, MSc, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy talks to St. Jude patient enrolled on the reported clinical trial, Corey Luellen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback